Drug Development Pipeline
TOBI® and BETHKIS® are aerosolized forms of the antibiotic tobramycin, which is used to treat people with CF who are chronically infected with Pseudomonas aeruginosa.
The FDA approved TOBI® in 1997 and BETHKIS® 2012 .
The TOBI® program was sponsored by Novartis Pharmaceuticals and funded by the Cystic Fibrosis Foundation. The BETHKIS® program was sponsored by Cornerstone Therapeutics. Both programs were conducted within the Therapeutics Development Network.
Recent Inhaled Tobramycin Studies
Completed with Results
Latest News on Inhaled Tobramycin
March 25, 2013
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More